Accelerating Uptake of Optimal Antiretrovirals for Children and Adolescents Living With HIV in Nigeria, Tanzania, Uganda and Zambia Through Data-driven Quality Improvement Interventions.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dowling Stephanie, Hackett Stephanie, Simao Lauren, Hast Marisa, Mehta Neha, Gross Jessica, Parris KaeAnne, Carpenter Deborah, Kama Jibrin, Mtui Leah, Mpasela Felton, Nabitaka Vennie, Adesigbin Clement, Adler Michelle, Arinaitwe Ivan, Atu Uzoma, Babyebonela Lilian, Birabwa Estella, Ene Uzoma, Johnson Fagbamigbe Omodele, Fenn Thomas, Habtezgi Simret, Haimbe Prudence, Ikpeazu Akudo, Itoh Megumi, John James, Kampamba Davies, Kwilasa Sylvester, Mabirizi David, Machage Edward, Magongo Eleanor, Mbonea Chediel, Mulenga Mwaba, Munthali Gloria, Musokotwane Kebby, Nakanwagi Miriam, Nantume Sophie, Nazziwa Esther, Ngwoke Kelechi, Nkolo Esther, Nta Iboro, Oladokun Oluwatosin, Olayiwola Olanrewaju, Oliver Daniel, Onotu Dennis, Onyenuobi Chibuzor, Rutaihwa Mastidia, Rwebembera Anath, Sam-Agudu Nadia A, Sowale Oluwakemi, Twinomujuni Evarist, Zyambo Khozya D, Suggu Kanchana, Amole Carolyn
Аннотация
METHODS: During January 2020-December 2021, FASTER supported treatment optimization in 245 high-burden facilities across Nigeria, Tanzania, Uganda and Zambia. We collected and analyzed quarterly ART uptake for CALHIV 0-19 years by regimen and weight band (3-19.9, 20-29.9 and ≥30 kg) as the primary outcome in FASTER-supported sites to inform course correction. We also analyzed VLS and viral load coverage among CALHIV between FASTER-supported and non-FASTER-supported sites.
RESULTS: Quarterly ART data analysis informed targeted ART training and mentorship of 1230 health workers and 4927 community members. A total of 225 facilities reported regimen data, covering 30,208 CALHIV. The proportion of CALHIV on optimized treatment regimens increased from 49.0%-66.4% at baseline to 82.6%-91.9% at endline across countries. VLS increased from 79% to 91% in FASTER sites and 77% to 90% in non-FASTER sites.
CONCLUSIONS: We saw dramatic improvements in optimal ART uptake overall. FASTER-supported interventions, such as data use and training, may have contributed to these increases. Optimal ART uptake likely contributed to improvements in VLS observed in both FASTER and non-FASTER sites given efforts to drive nationwide scale-up of optimal ART.